Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience

BACKGROUND: Vedolizumab, which is a monoclonal antibody that selectively binds to α4β7 integrin in the gastrointestinal system, may be an effective and safe treatment alternative in those with anti-tumor necrosis factor-resistant inflammatory bowel disease. METHODS: Patients administered vedolizumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Erdoğan, Çağdaş, Yeşil, Bayram, Bacaksız, Ferhat, Arı, Derya, Gökbulut, Volkan, Yüksel, Mahmut, Özin, Yasemin Özderin, Kayaçetin, Ertuğrul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Turkish Society of Gastroenterology 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623212/
https://www.ncbi.nlm.nih.gov/pubmed/35946879
http://dx.doi.org/10.5152/tjg.2022.21684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623212/
https://www.ncbi.nlm.nih.gov/pubmed/35946879
http://dx.doi.org/10.5152/tjg.2022.21684

Ejemplares similares